Expanding HIF Prolyl Hydroxylase Inhibitors to New Therapeutic Applications

Publication ID: 24-11857543_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Expanding HIF Prolyl Hydroxylase Inhibitors to New Therapeutic Applications,” Published Technical Disclosure No. 24-11857543_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857543_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,543.

Summary of the Inventive Concept

The present inventive concept explores novel uses of HIF prolyl hydroxylase inhibitors beyond anemia treatment, targeting athletic performance, cognitive function, fatigue reduction, sleep quality, and muscle recovery.

Background and Problem Solved

The original patent focused on treating anemia secondary to chronic kidney disease, chemotherapy, and AIDS. However, the limitations of this patent lie in its narrow scope, neglecting potential applications in other fields. The present inventive concept addresses this limitation by applying HIF prolyl hydroxylase inhibitors to entirely new therapeutic areas.

Detailed Description of the Inventive Concept

The new claims introduce novel uses of HIF prolyl hydroxylase inhibitors in various fields. For instance, Claim 1 proposes a system for monitoring and optimizing athletic performance by administering the inhibitor and measuring hemoglobin levels. Similarly, Claims 2-5 explore the inhibitor's potential in enhancing cognitive function, reducing fatigue, improving sleep quality, and enhancing muscle recovery. These new applications leverage the inhibitor's ability to modulate HIF signaling pathways, unlocking new therapeutic possibilities.

Novelty and Inventive Step

The inventive concept's novelty lies in its unexpected application of HIF prolyl hydroxylase inhibitors to new therapeutic areas, demonstrating an inventive step beyond the original patent's scope. The new claims introduce a paradigm shift in the understanding of the inhibitor's potential, moving beyond anemia treatment to address unmet needs in various fields.

Alternative Embodiments and Variations

Alternative embodiments may include varying the dosage, administration route, or composition of the HIF prolyl hydroxylase inhibitor. Additionally, the inventive concept could be adapted to other diseases or conditions where HIF signaling plays a crucial role, such as cancer, cardiovascular disease, or neurodegenerative disorders.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential, targeting lucrative markets in athletic performance, cognitive function, and chronic disease management. The potential market size is substantial, with opportunities for partnerships, licensing, and product development in various industries.

Original Patent Information

Patent NumberUS 11,857,543
TitleCompositions and methods for treating anemia
Assignee(s)Akebia Therapeutics, Inc.